Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study.

ABSTRACT:

Introduction

Our objective was to compare the predictive performance of the Fetal Medicine Foundation (FMF) competing-risk model for preterm preeclampsia (PE) screening using placental growth factor (PlGF) measurements obtained at 11-13⁺⁶ weeks versus before 11 weeks of gestation.

Material and methods

This multicenter prospective cohort study included women with singleton pregnancies attending their routine first-trimester assessment (11⁺⁰ to 13⁺⁶ weeks) in four hospitals across Spain from 2021 to 2023. Maternal characteristics, biophysical parameters (mean arterial pressure and uterine artery pulsatility index), and biochemical markers (PlGF measured twice in each woman, before 11 weeks and between 11 and 13⁺⁶ weeks) were assessed

SUBMITTER: Lopez Marmol R 

PROVIDER: S-EPMC12451210 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature